University Hospitals announces first commercial implant in the U.S. of The Evolut PRO transcatheter heart valve

Thursday, May 11, 2017
CLEVELAND New surgical options are only as good as they make you feel once you leave the operating room. One of the biggest post-operative issues with the usually sound transaortic valve replacements (TAVR) was that the newly inserted valve allowed leakage that created poor outcomes.
University Hospitals announced that its surgeons completed the first commercial implant  in the United States of the newly FDA approved TAVR valve called the CoreValveEvolut PRO for the treatment of severe symptomatic aortic stenosis. Recently unveiled clinical data showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve.
The Evolut PRO device features a unique valve design with an outer wrap that adds surface area contact between the valve and the native aortic annulus to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence of blood leaking through the sides of the valve.

Download full release

<< Back
  • News Media Access

  • Register
  • Forgot My Password
  • Search:

    Advanced Search

  • Subscribe To Our Latest News

    Subscribe to University Hospitals' RSS Feeds or Email Alerts to get our latest news.

    University Hospitals RSS Feed  University Hospitals Email Alerts
  • Twitter

    Must select a Twitter Account for Rail Gadget in Twitter Tool.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.